Biofrontera AG (B8F.DE)

0.55 €

+0.03 (+0.00%)
Symbol B8F.DE
Price 0.55 €
Beta 0.871
Volume Avg. 0.01M
Market Cap 35.094M
Shares () -
52 Week Range 0.47-1.71
1y Target Est -
DCF Unlevered B8F.DE DCF ->
DCF Levered B8F.DE LDCF ->
ROE -59.99% Strong Sell
ROA -38.33% Strong Sell
Operating Margin -
Debt / Equity 7.64% Neutral
P/E -4.23 Strong Sell
P/B 2.24 Strong Buy


Consensus EPS

Upgrades & Downgrades

Ms. Pilar de la Huerta Martinez
Drug Manufacturers—Specialty & Generic
Frankfurt Stock Exchange

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.